Quest Diagnostics Incorporated(DGX)
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest News & Analysis
Quest Diagnostics Raises Dividend as Organic Growth Accelerates
Dividend increase to USD 0.80/quarter signals confidence as precision medicine adoption and LifeLabs integration drive organic growth above 5%.
Quest Diagnostics: Market Trends, Innovation, and Future Outlook
Quest Diagnostics navigates market dynamics with strategic collaborations and innovation, focusing on growth in diagnostics and Alzheimer's research.
Quest Diagnostics: Innovation and Leadership 2025
Comprehensive update on DGX's latest innovations, strategic partnerships, Q4 earnings, and market trends driving diagnostic growth.
Quest Diagnostics: Strategic Acquisitions, Cancer Detection, and Market Outlook
Quest Diagnostics strategically expands with Spectra Laboratories acquisition and GRAIL partnership, innovating in Alzheimer's diagnostics. Investor Day insights awaited.
Quest Diagnostics: Strategic Expansion, Innovation, and Future Outlook
Quest Diagnostics strategically expands through acquisitions, partnerships, and innovation in Alzheimer's and cancer diagnostics. Investor Day 2025 promises insights into future strategies.
Quest Diagnostics: Strategic Acquisitions, Cancer Detection, and Investor Day Preview
Quest Diagnostics expands through strategic acquisitions and partnerships, focusing on cancer and Alzheimer's diagnostics. Investor Day preview and financial analysis included.
Quest Diagnostics (DGX): Strategic Acquisitions, Investor Day Preview, and Market Outlook
Quest Diagnostics (DGX) navigates strategic acquisitions, innovation, and an upcoming Investor Day, shaping its diagnostic leadership and market outlook.
Quest Diagnostics (DGX): Developments, Market Impact, and Outlook
Quest Diagnostics (DGX) navigates growth via strategic acquisitions and advanced diagnostics amidst debt management and healthcare policy shifts. Investor Day 2025 insights awaited.
DGX Analysis: Quest Diagnostics' Growth Strategy and Market Position
Quest Diagnostics (DGX) is strategically expanding its diagnostic capabilities through acquisitions, partnerships, and innovation, positioning itself for future growth.
Quest Diagnostics (DGX): Growth Strategy and Market Analysis
Quest Diagnostics is strategically positioned for growth through market expansion, advanced diagnostics, and partnerships, driving long-term shareholder value.
Quest Diagnostics (DGX): AI, Partnerships, and the Future of Diagnostics
Quest Diagnostics (DGX) is strategically positioned for future growth through AI integration, expansion into early cancer detection, and strategic acquisitions.
Quest Diagnostics (DGX): Innovation, AI, and Market Analysis
Quest Diagnostics (DGX) navigates market shifts with strategic innovation, AI integration, and expanding diagnostic services, despite a recent stock dip.
Quest Diagnostics (DGX): MD Anderson Collaboration & Q1 2025 Analysis
Quest Diagnostics' recent MD Anderson collaboration for a multi-cancer test signals a strategic pivot into high-growth oncology diagnostics.
Quest Diagnostics (DGX): Strategic Pivot in Cancer Diagnostics
Quest Diagnostics is pioneering cancer diagnostics with its MD Anderson collaboration, aiming for early detection and robust financial growth.
Quest Diagnostics (DGX): MCaST Blood Test Redefines Cancer Screening
Quest Diagnostics' MCaST blood test, developed with MD Anderson, marks a significant strategic pivot, aiming to redefine multi-cancer screening.
Quest Diagnostics (DGX) Advances Cancer and Alzheimer's Diagnostics with Strong Q1 Financials
Quest Diagnostics partners with MD Anderson for cancer blood test MCaST and launches AD-DETECT™ for Alzheimer's, showing robust Q1 2025 growth and strategic innovation.
Quest Diagnostics (DGX): Strategic Moves and Financial Snapshot
Quest Diagnostics' strategic moves in cancer and women's health diagnostics, coupled with recent financial performance, signal key shifts for investors.
Quest Diagnostics (DGX) Q1 2025 Analysis: Advanced Diagnostics Drive Growth and Market Leadership
Quest Diagnostics' Q1 2025 growth is fueled by advanced diagnostics innovation, strategic acquisitions, and pioneering cancer and Alzheimer's tests, strengthening its market position.
Quest Diagnostics (DGX) Advances Alzheimer's Diagnostics, Strengthening Market Leadership
Quest Diagnostics expands into high-margin Alzheimer's and oncology diagnostics with FDA-cleared blood tests, driving strong Q2 earnings outlook and stock resilience.
Quest Diagnostics Inc (DGX) Advanced Diagnostics Growth Driven by FDA-Cleared Alzheimer's Test
Quest Diagnostics propels advanced diagnostics with FDA-cleared Alzheimer's blood test, boosting specialized testing revenue amid solid financial performance.
Quest Diagnostics (DGX) Strategic Growth in Advanced Diagnostics and Financial Health Insights
Quest Diagnostics (DGX) advances in Alzheimer's, oncology, and infectious disease diagnostics, backed by solid financials and strategic acquisitions.
Quest Diagnostics 2025 Q2 Update: Strategic Growth and Financial Insights by Monexa AI
Quest Diagnostics reports strong Q2 2025 results driven by LifeLabs acquisition, advanced diagnostics growth, and automation improving margins and operational efficiency.
Quest Diagnostics Q2 2025 Analysis: Strategic Acquisitions and Automation Drive Growth | Monexa AI
Quest Diagnostics Q2 2025 shows strong 10% revenue growth led by LifeLabs acquisition and automation gains, underscoring solid market positioning and margin expansion.
Quest Diagnostics Q2 2025 Earnings and Strategic Growth Analysis | Monexa AI
Quest Diagnostics (DGX) posts strong Q2 2025 results with 15.2% revenue growth, raised guidance, and strategic advances in advanced diagnostics and AI integration.
Quest Diagnostics (DGX) Strategic Acquisitions and Diagnostics Innovations Driving Growth in 2025
Quest Diagnostics advances 2025 growth via Spectra Labs acquisition, renal diagnostics expansion, and innovation in neurology and oncology testing.
Quest Diagnostics Incorporated (DGX) Q2 2025 Growth Strategy and Financial Performance Analysis
Quest Diagnostics' strategic pivot to high-margin advanced diagnostics, bolstered by strong Q2 2025 results and key acquisitions, drives sustained revenue and EPS growth.
Quest Diagnostics (DGX): Q2 Beat, Debt and Growth Trade-offs
Quest reported a stronger‑than‑expected Q2 2025 — **$2.76B revenue, +15.2% YoY** — but elevated leverage (net debt **$6.54B**) and integration costs make execution the key risk.
Quest Diagnostics (DGX): Breakthrough MRD, M&A-Fueled Growth and a Heavier Balance Sheet
FDA Breakthrough for Haystack MRD and a completed Spectra asset deal sharpen Quest’s growth story; 2024 financials show steady revenue (+6.70%) but leverage rising to **~3.46x** net-debt/EBITDA on FY figures.
Quest Diagnostics (DGX): Revenue Upside, Heavy M&A and a Debt Trade-off
Quest Diagnostics reported **FY2024 revenue of $9.87B (+6.70% YoY)** while net debt rose to **$6.54B (+36.00%)** after $2.16B of acquisitions—what that means for growth, margins and cash flow.